THERALASE TECH INC COM NPV (OTCMKTS:TLTFF) is a biotech player that has been focused on the commercialization of medical devices for the elimination of pain as well as the development of Photo Dynamic Compounds to destroy or contain and treat cancerous conditions. TLTFF just jumped higher this week. The only clear associated catalyst was the company’s announcement that at the Maximum Recommended Starting Dose (0.35 mg/cm2) of its lead compound, TLD-1433, at the ninety-day cystoscopy analysis “has achieved the exploratory endpoint of efficacy in patients inflicted with Non-Muscle Invasive Bladder Cancer.”
According to the release, “The exploratory outcome endpoint in the Study is Recurrence-Free Survival (“RFS”). RFS is defined as the interval from Day 0 (Day of treatment with TLD-1433 Photo Dynamic Therapy (“PDT”)) to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e. any biopsy-confirmed new or recurrent tumour), evaluated at ninety (90) days for the first three (3) patients treated at the MRSD (0.35 mg/cm2) and primarily at ninety (90) days for the next six (6) patients treated at the Therapeutic Dose (0.70 mg/cm2) and secondarily at one hundred and eighty (180) days post treatment.”
THERALASE TECH INC COM NPV (OTCMKTS:TLTFF) bills itself as a company that designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions.
Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which localize to cancer cells and then when laser light activated, effectively destroy them.
According to company materials, “Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.”
Find out when $TLTFF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Dr. Arkady Mandel, Chief Scientific Officer of the Company stated, “The achievement of the exploratory outcome measure of efficacy for the treatment of NMIBC at ninety (90) days, in the first three (3) patients treated, for the first part of the Study, by the Company is extremely encouraging. I look forward to following the clinical reports and complete patient data to further validate these results at the scheduled clinical analyses defined by the approved clinical protocol.”
Dr. Mandel continued, “Theralase’s PDT approach is demonstrating remarkable safety, tolerability and efficacy for the Bacillus Calmette-Guérin (“BCG’) refractory and highly recurrent papillary (Ta) transitional cell carcinoma NMIBC population. Since the PDT procedure has been well tolerated and patients are able to undergo a repeat of the procedure, if required, this PDT treatment offers considerable therapeutic advantages.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “The Company is ecstatic that after decades of hard work the Company, in the first 3 patients treated, at the 90 day cystoscopy follow-up, at a MRSD (0.35 mg/cm2) of TLD-1433, that the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and now exploratory endpoint of efficacy have been achieved. I wish to thank the entire Theralase board and employees, the clinical and scientific team and the Medical and Scientific Advisory Board, who have provided their knowledge, experience and worked tirelessly to make this day a reality.”
Recent action has seen 24% added to share values of the stock over the past month of action. This is emblematic of the stock. TLTFF has a track record that includes a number of dramatic bounces. Furthermore, the company has seen an influx in interest of late, with the stock’s recent average trading volume running greater than 100% above the average volume levels in play in this stock over the longer term.
Currently trading at a market capitalization of $44.7M, TLTFF has a reported store ($1.6M) of cash on the books, which compares with virtually no total current liabilities. TLTFF is pulling in trailing 12-month revenues of $2M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 23.3%. This may be a very interesting story and we will look forward to updating it again soon. For continuing coverage on shares of $TLTFF stock, as well as our other breakout picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $TLTFF, either long or short, and we have not been compensated for this article.